Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - Deferred ChargesAmortization - IntangiblesConsolidated Net IncomeDepreciation & Amortization - TotalEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Verastem (VSTM) EBIT (2018 - 2025)

Historic EBIT for Verastem (VSTM) over the last 8 years, with Q3 2025 value amounting to -$40.7 million.

  • Verastem's EBIT fell 995.14% to -$40.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$160.2 million, marking a year-over-year decrease of 5308.62%. This contributed to the annual value of -$115.0 million for FY2024, which is 2483.82% down from last year.
  • Latest data reveals that Verastem reported EBIT of -$40.7 million as of Q3 2025, which was down 995.14% from -$43.8 million recorded in Q2 2025.
  • Over the past 5 years, Verastem's EBIT peaked at -$14.1 million during Q1 2021, and registered a low of -$44.2 million during Q1 2025.
  • In the last 5 years, Verastem's EBIT had a median value of -$19.8 million in 2023 and averaged -$24.4 million.
  • Over the last 5 years, Verastem's EBIT had its largest YoY gain of 4647.75% in 2021, and its largest YoY loss of 19886.13% in 2021.
  • Over the past 5 years, Verastem's EBIT (Quarter) stood at -$16.5 million in 2021, then dropped by 2.03% to -$16.8 million in 2022, then fell by 26.49% to -$21.3 million in 2023, then crashed by 48.25% to -$31.6 million in 2024, then decreased by 28.89% to -$40.7 million in 2025.
  • Its last three reported values are -$40.7 million in Q3 2025, -$43.8 million for Q2 2025, and -$44.2 million during Q1 2025.